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Intravenous iron increases labile serum iron but does not impair
forearm blood flow reactivity in dialysis patients.
Background. There are concerns about adverse vascular ef-
fects of intravenous iron by inducing oxidative stress. We there-
fore examined the effect of a single high dose of intravenous
iron on endothelial function and biochemical markers of iron
homeostasis.
Methods. In a randomized, placebo-controlled, double-blind,
parallel-group study, forearm blood flow (FBF) was assessed by
strain-gauge plethysmography in 38 peritoneal dialysis patients
before and after a single intravenous infusion of 300 mg iron
sucrose.
Results. Iron infusion increased total ( 601 lg/100 mL, CI
507, 696) and non–transferrin-bound iron ( 237.2 lmol/L, CI
173.6, 300.8) approximately 10-fold, as well as redox-active iron
nearly five-fold ( 0.76 lmol/L, CI 0.54, 0.98). After iron in-
fusion basal FBF was 59% higher than after placebo. FBF re-
sponse to acetylcholine before and after iron infusion was 263 ±
32% and 310 ± 33%, corresponding to 304 ± 43% and 373 ±
29% in the placebo group, respectively. Before and after iron
or placebo infusion, glyceryl-trinitrate increased resting FBF to
232 ± 22% and 258 ± 21% in the iron group, and to 234 ±
18% and 270 ± 30% in the placebo group. L-N-monomethyl-
arginine decreased FBF to 70 ± 4% and 72 ± 3% before and
after iron, and to 74 ± 4% and 73 ± 4% before and after placebo
infusions, respectively. Despite higher basal FBF after iron infu-
sion, absolute and relative FBF changes in response to vasoac-
tive substances were not significantly different between iron and
placebo groups.
Conclusion. Our data suggest that 300 mg intravenous iron
sucrose has a vasodilatory effect, but does not impair vascular
reactivity in dialysis patients, despite a significant increase in
non–transferrin-bound and redox-active iron.
Sufficient iron substitution is critical for adequate
treatment of anemia, especially in erythropoietin-treated
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renal failure patients [1–4]. Because oral iron is poorly
absorbed, intravenous iron supplementation is preferred
in most of these patients [5]. While the prevalence of
iron deficiency is lower in peritoneal dialysis (PD) com-
pared to hemodialysis (HD) patients, PD patients receive
higher bolus doses of iron at longer intervals since they
only visit the center every four to six weeks. Further-
more, unlike HD patients, PD patients often have limited
venous access and their forearm veins need to be kept
permeable. When infused over a period of two hours,
iron sucrose in single doses of up to 300 mg has been
well tolerated in dialysis patients [6]. There are, however,
concerns about intravenous iron administration. A sin-
gle bolus of 300 mg of intravenous iron sucrose has been
reported to depress phagocyte function in PD patients
[7]. Impairment of neutrophil function is also present in
chronic HD patients receiving intravenous iron therapy,
especially in those with ferritin levels above 650 lg/L [8].
Therefore, high-dose or long-term intravenous iron ad-
ministration may be associated with an increased risk of
infection [9]. Furthermore, increased blood levels of non–
transferrin-bound iron (NTBI) or its redox-active part
may cause endothelial dysfunction and platelet activation
by generation of reactive oxygen species, inactivation of
endothelium-derived nitric oxide (NO), and oxidation of
low-density lipoproteins (LDL) [10–12]. These are impor-
tant mechanisms in the pathogenesis of atherosclerosis
[13].
To date, there are no sufficient studies available that
have addressed the effect of high dose intravenous iron
on endothelial function and redox-active iron. We there-
fore investigated whether one single intravenous dose of
300 mg of iron sucrose acutely deteriorates vascular func-
tion in stable PD patients.
METHODS
The study was approved by the Ethics Committee of
the Medical University Vienna and conforms with the
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principles outlined in the Declaration of Helsinki, in-
cluding current revisions and the European Guidelines
on Good Clinical Practice.
Study population
Thirty-eight patients treated with continuous ambula-
tory (CAPD, N = 16) or automated (APD, N = 22) peri-
toneal dialysis at the Medical University Vienna, from
whom written informed consent was obtained before
enrollment, were included consecutively in order of at-
tendance over a period of seven months. Patients were
18 years of age or older, had been stable on PD for at least
three months, and without an episode of peritonitis for at
least 2 months before inclusion. Furthermore, none of the
patients received oral or intravenous iron preparations
for at least six weeks before study begin. Erythropoietin-
treated patients were included if hemoglobin levels were
≤14 g/100 mL and ferritin ≤500 lg/L. Patients without
erythropoietin therapy were included if hemoglobin was
≤12 g/100 mL and ferritin ≤500 lg/L, or with hemoglobin
between 12 and 14 g/100 mL if ferritin levels were below
200 lg/L.
Exclusion criteria were participation in another trial
within 4 weeks before study begin, allergy or intolerance
to iron sucrose, poor general condition of health, acute
infection, acute vascular disease (history of stroke, my-
ocardial infarction, or peripheral occlusive disease within
three months before start of the study), and pregnancy.
Coronary artery disease was defined as history of per-
cutaneous or surgical revascularization and/or myocar-
dial infarction. Accordingly, peripheral vascular disease
and cerebrovascular arterial disease were defined as his-
tory of percutaneous or surgical revascularization and/or
gangrene or cerebral stroke, respectively. Hypertension
was defined as blood pressure higher than 140/90 mm Hg
and/or use of antihypertensive medication. Study groups
were well balanced with respect to concomitant diseases.
Arterial hypertension was the most common medical his-
tory (N = 18 in both study groups), followed by coronary
heart disease (N = 4 in both patient groups) and diabetes
mellitus (N = 3 in iron group, N = 4 in placebo group). No
patient had a history of peripheral vascular disease. One
patient in the iron group and two patients in the placebo
group had a history of cerebrovascular disease. Smoking
(3 and 5 subjects) and statin therapy (8 and 11 subjects)
were equally distributed between groups. One subject re-
ceiving iron and six subjects receiving placebo reported
intake of chronic vitamin supplementation (low dose fo-
late and/or vitamin B12 and/or vitamin B6). All patients
except one in the iron group and two in the placebo group
received erythropoietin-beta or darbepoetin-alfa subcu-
taneously. For detailed patient characteristics see Table 1.
Smokers were asked not to smoke for 12 hours be-
fore and during the study day. Patients were asked to
Table 1. Baseline characteristics for PD patients receiving 300 mg
intravenous iron sucrose or placebo infusion
Iron Placebo
(N = 19) (N = 19)
Age years 57 ± 11 56 ± 14
Sex m/f 15/4 13/6
BMI kg/m2 26.8 ± 3.1a 23.9 ± 3.8
CAPD N 9 7
APD N 10 12
Duration of PD months 16 ± 11 20 ± 16
RRF mL/min 6.10 ± 2.79 6.19 ± 3.73
Kt/Vurea 2.59 ± 0.56 2.72 ± 0.76
BMI, body mass index; CAPD, continuous ambulatory peritoneal dialysis;
APD, automated peritoneal dialysis; PD, peritoneal dialysis; RRF, residual renal
function; Kt/Vurea, weekly urea clearance over total body water. Mean ± SD.
aP < 0.05 vs. placebo.
fast at least for 10 hours before measurement of vascu-
lar function. All subjects continued their regular medi-
cation. Studies were conducted in a quiet room with an
ambient temperature of 22◦C with complete resuscitation
facilities.
Outcomes
The primary end point was forearm blood flow
(FBF) reactivity in PD patients after intravenous infu-
sion of 300 mg of iron sucrose compared to placebo
administration.
Secondary end points were effect on serum concen-
trations of total iron, non–transferrin-bound iron, and
redox-active iron after intravenous iron infusion com-
pared to placebo infusion.
Forearm blood flow measurements
Forearm blood flow was measured in both arms, as de-
scribed previously [14, 15]. Briefly, strain gauges, placed
on the forearms, were connected to plethysmographs
(EC-6, D.E. Hokanson, Bellevue, WA, USA) to measure
changes in forearm volume in response to inflation of ve-
nous congesting cuffs. Drug effects were expressed as the
ratio of blood flow in the intervention to the control arm
[15, 16], where predose ratio was defined as 100%. Wrist
cuffs were inflated to suprasystolic pressures during each
measurement to exclude circulation to the hands. Flow
measurements were recorded for 9 seconds at 30-second
intervals during drug infusions.
Study design
The study followed a prospective, randomized, double-
blind, placebo-controlled, parallel-group design. Patients
were randomized into one of the following two groups:
patients of the iron group (N = 19) received a single
dose infusion of 300 mg of iron sucrose (Venofer, Vifor,
Levallois-Perret, France) in 50 mL 0.9% sodium chloride
solution over two hours. Patients of the placebo group
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(N = 19) received 50 mL vehicle alone. Measurements
of endothelial function were done identically in both
groups, before and immediately after iron/placebo infu-
sion. In both patient groups, blood samples were taken at
baseline and after infusion. Additionally, 24-hour urine
and dialysate samples were taken for clearance measure-
ments before start of the study.
A sample size calculation was carried out prior to the
study. To detect a 75% difference in vascular function be-
tween iron sucrose or placebo, and assuming a type I error
of 0.05, a power of 80%, and a dropout of two patients
per group, a sample size of 38 patients (19 per group) was
estimated.
Randomization and double-blinding
The random allocation sequence was generated using
the web site www.randomization.com. Patients were en-
rolled by one of the investigators. Infusions were pre-
pared in black nontransparent syringes and infusion lines
by study nurses not involved in administration of drugs or
measurement of vascular function. Infusions of iron and
placebo were given by study nurses. Nurses and inves-
tigators who performed infusions and/or measurements
of vascular function as well as patients and laboratory
personnel were blinded to group assignment.
Experimental protocol
A fine-bore needle (27G needle Sterican; B. Braun,
Melsungen, Germany) was inserted into the brachial
artery of the left arm for the administration of vasodila-
tors. After a 10-minute resting period, FBF during in-
fusion of 0.9% saline was measured for five minutes,
followed by measurements of FBF response to incremen-
tal doses of the endothelium-dependent dilator acetyl-
choline (ACh, Clinalfa, La¨ufelfingen, Switzerland; 25,
50, and 100 nmol/min for 3 minutes per dose level). Af-
ter a 15-minute washout period with intra-arterial saline
infusions to allow restoration of predose blood flow,
the response to the endothelium-independent dilator
glyceryl-trinitrate (GTN, Perlinganit; Gebro Pharma,
Fieberbrunn, Austria; 4, 8, 16 mmol/min for 3 minutes
per dose level) was measured. After another 15-minute
washout period, this was repeated for the endothelium-
dependent vasoconstrictor and NO-synthase inhibitor
L-N-monomethyl-arginine (L-NMMA; Clinalfa, 1, 2,
4 lmol/min for 3 minutes per dose level).
Subsequently, a plastic cannula was inserted into an an-
tecubital or dorsal hand vein for a baseline blood draw.
The cannula was then used for administration of iron su-
crose or placebo over 120 minutes. Immediately after the
end of infusion, blood was collected from the other arm
by a fresh venipuncture.
Forearm blood flow responses to endothelium-
dependent and endothelium-independent dilators and to
L-NMMA were repeated in a manner identical to the
measurements obtained before iron sucrose or placebo
infusions.
As safety parameters, arterial blood pressure and pulse
rate were recorded.
Measurement of mobilizer-dependent NTBI
and redox-active iron
Mobilizer-dependent non–transferrin-bound iron was
measured according to the method published by Breuer
et al [17], using desferrioxamine (DFO, Desferal;
Novartis, Vienna, Austria) as iron chelator and oxalate
as iron mobilizing agent. The binding of NTBI from
the sera to DFO-coated wells was detected with a non-
fluorescent iron-calcein complex. Calcein has a lower
affinity to iron than DFO and can donate iron to DFO
not occupied by NTBI from the serum of patients. There-
fore, calcein becomes iron free. Fluorescence of iron-
free calcein was measured in a fluorescence multiwell
plate reader (Victor2 from Wallac, Turku, Finland—
now Perkin-Elmer, Boston, MA, USA) with excita-
tion/emission filters of 485/530 nm.
Redox-active iron was measured with slight modifi-
cations as described by Esposito et al [18], based on
the principle that dichlorofluorescine (DCF; Molecular
Probes, Inc., Eugene, OR, USA) is converted from its
nonfluorescent to fluorescent form by several oxidants. In
brief, patient sera (20 lL) were transferred in quadrupli-
cates to black, clear-bottom 96-well plates (Greiner, Bio-
one, Graz, Austria). Two wells were incubated with iron
free HEPES buffered saline (HBS) (20 mmol/L HEPES,
150 mmol/L NaCl, pH 7.4; Merck, Darmstadt, Germany)
containing 150 lmol/L ascorbate and 5 lmol/L DCF at
37◦C in the dark. The other two wells were incubated
with 180 lL of the same solution containing 50 lmol/L
of the iron chelator Deferiprone (L1; kindly provided by
Dr. Peter Nielsen, UKE, Hamburg, Germany). HBS was
rendered iron free by treatment with 1 g/100 mL Chelex-
100 (Sigma-Aldrich, Vienna, Austria). The kinetics of flu-
orescence increase were measured in the fluorescence
multiwell plate reader. Measurements between 60 and
120 minutes were used to calculate slopes (r) of DCF flu-
orescence intensity over time. The fluorescence increase
measured in presence of L1 represents oxidation of DCF
by several other oxidants (e.g., peroxidases or hypochlor-
ous acid generated by myeloperoxidases). Therefore, the
difference in the rate of oxidation of DCF with and with-
out addition of the chelator L1 represents the redox-
active component of NTBI. The duplicate values of r with
and without addition of L1 were averaged, and redox-
active iron (in lmol/L) was determined from calibration
curves correlating the difference in slopes with and with-
out L1 against the iron concentration.
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Other biochemical methods
Plasma samples for non–transferrin-bound and redox-
active iron were taken at baseline (before start of infu-
sion) and after 120 minutes (immediately after end of
infusion). Plasma samples were batch analyzed. Com-
plete blood counts as well as blood, dialysate, and urine
chemistry were performed by standard procedures in an
ISO 9001:2000 certified laboratory. Serum iron was mea-
sured using a Hitachi 747 analyzer (Roche Diagnostics,
Mannheim, Germany). Serum transferrin concentrations
were determined by the Behring Nephelometer II an-
alyzer (Dade Behring, Liederbach, Germany). Serum
ferritin levels were analyzed with a Hitachi 911 instru-
ment (Roche Diagnostics). Transferrin saturation was
calculated as follows: serum iron (lg/100 mL)/serum
transferrin (mg/100mL) × 70.9. Concentrations of to-
tal homocysteine (tHcy) were measured by a fluo-
rescence polarization immunoassay (IMx Analyzer;
Abbott, Wiesbaden, Germany).
Statistical methods
All data were tested for normal distribution and com-
pared using Student paired or unpaired t test, if appro-
priate. Data with log-normal distribution were compared
using the Mann Whitney U test. Forearm blood flow mea-
surements were calculated as mL/min/100 mL forearm
volume and expressed as percent change from predose
ratio. The effects on intra-arterial ACh, GTN, and L-
NMMA were assessed by analysis of variance (ANOVA)
for repeated measurements, followed by Bonferroni cor-
rected t tests. Statistical analysis was carried out using the
Statistica software package (release 6.0; StatSoft, Inc.,
Tulsa, OK, USA). P < 0.05 was considered significant.
Values are expressed as mean ± SEM unless indicated
otherwise.
RESULTS
Laboratory results
Baseline laboratory values were comparable between
study groups, with the exception of calcium × phospho-
rous ion product (Ca×P) and LDL cholesterol, which
were higher in subjects receiving iron. For detailed re-
sults see Table 2.
Iron status
At baseline, total iron was lower in the iron group.
As expected, total iron increased after infusion of iron
sucrose, total iron was 601 lg/100 mL (95% confidence
interval CI 507, 696; P < 0.01) compared to 0 lg/100 mL
(CI −5, +5) in the placebo group (P < 0.01 vs. iron group).
Transferrin (TRF) was higher and transferrin saturation
(TSAT) lower in the iron group at baseline (Table 2).
Table 2. Baseline laboratory parameters for PD patients receiving
300 mg intravenous iron sucrose or placebo infusion
Iron Placebo
(N = 19) (N = 19)
Hemoglobin g/100mL 12.2 ± 1.0 12.2 ± 1.0
Leukocytes 109/L 6.8 ± 1.4 6.9 ± 2.2
Platelets 109/L 228 ± 69 230 ± 77
Total iron lg/100mL 60 ± 25a 79 ± 25
Transferrin mg/100mL 197 ± 37a 171 ± 20
Transferrin saturation% 22.81 ± 10.82a 33.33 ± 11.57
Ferritin lg/L 140 ± 103 202 ± 100
Redox-active iron lmol/L 0.22 ± 0.04 0.21 ± 0.03
NTBI lmol/L 28.5 ± 83.7 74.1 ± 131.1
Bicarbonate mmol/L 23.9 ± 2.3 23.2 ± 1.8
PTH pg/mL 330.8 ± 303.4 367.0 ± 238.8
Ca×P mmol2/L2 4.68 ± 0.95a 4.02 ± 0.63
Homocysteine lmol/L 25.4 ± 5.9 25.0 ± 8.9
C-reactive protein mg/100mL 0.85 ± 0.49 0.68 ± 0.25
Albumin g/L 35.8 ± 4.3 36.4 ± 3.9
Total cholesterol mg/100mL 212 ± 57 183 ± 42
LDL cholesterol mg/100mL 136 ± 49a 104 ± 40
HDL cholesterol mg/100mL 44 ± 14 50 ± 16
Triglycerides mg/100mL 189 ± 135 163 ± 110
NTBI, non–transferrin-bound iron; PTH, parathyroid hormone; Ca×P,
calcium × phosphorous ion product calculated as serum calcium (mmol/L) ×
serum phosphate (mmol/L). Mean ± SD.
aP < 0.05 vs. placebo.
In patients with iron infusion, TRF was −16 mg/
100 mL (CI −27, −5; P = NS) and in patients with placebo
−2 mg/100 mL (CI −11, 7; P = NS) (P < 0.05 between
groups). Since calculated TSAT after intravenous iron
administration reflects both transferrin-bound iron and
iron bound to circulating iron agent, we did not include
TSAT in our results. Ferritin levels were not different
between groups before or after iron infusion. Within the
iron group, ferritin levels increased slightly, with ferritin
of 16 lg/L (CI 2, 30; P = NS) versus ferritin −4 lg/L (CI
−17, 8; P = NS) in the placebo group. Non–transferrin-
bound iron was not different between groups at baseline,
NTBI was 237.2 lmol/L (CI 173.6, 300.8; P < 0.01) after
administration of iron sucrose, compared to –18.8 lmol/L
(CI −74.2, 36.3; P = NS) after placebo (P < 0.01 between
groups) (Fig. 1). Levels of redox-active iron were not dif-
ferent at baseline, redox-active iron was 0.76 lmol/L
(CI 0.54, 0.98; P < 0.01) in the iron group, compared to
−0.005 lmol/L (CI −0.02, 0.01; P = NS) in the placebo
group (P < 0.01 vs. iron group) (Fig. 2).
Basal forearm blood flow
Mean basal blood flow in both forearms before infu-
sions was 3.81 mL/min/100 mL (CI 2.94, 4.68) in the iron
and 3.12 mL/min/100mL (CI 2.64, 3.61) in the placebo
group (P = NS between groups) (Fig. 3). After infu-
sion of 300 mg iron sucrose basal FBF was 3.73 mL/min/
100 mL (CI 3.04, 4.42), which was 59% higher than the
2.34 mL/min/100 mL (CI 1.94, 2.75; P < 0.05 vs. base-
line, P < 0.01 vs. iron) after placebo infusion. FBF
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Fig. 1. Non-transferrin bound iron (NTBI, lmol/L) before and after
infusion of 300 mg of iron sucrose over two hours (hatched columns,
N = 19) or placebo (open columns, N = 19). Mean ± SEM. ∗P < 0.01
vs. baseline and between groups.
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Fig. 2. Redox-active iron (lmol/L) before and after infusion of 300 mg
of iron sucrose over two hours (hatched columns, N = 19) or placebo
(open columns, N = 19). Mean ± SEM. ∗P < 0.01 vs. baseline and
placebo.
was −0.11 mL/min/100 mL (CI −0.70, 0.49) in the iron
and −0.78 mL/min/100 mL (CI −1.29, −0.26) in the
placebo group (P = 0.08 between groups, t test; P = NS,
Bonferroni corrected post-hoc test).
Forearm blood flow reactivity
Acetylcholine caused a dose-dependent increase in
FBF to a maximum of 263 ± 32% and 304 ± 43% be-
fore iron or placebo infusion, respectively (P = NS be-
tween groups). Responses were comparable after drug in-
fusions, with 310 ± 33% after iron sucrose, and 373 ± 29%
after placebo (P = NS vs. baseline and between groups)
(Fig. 4).
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Fig. 3. Basal forearm blood flow (FBF) before and after infusion of
300 mg of iron sucrose (hatched columns) or placebo (open columns).
Mean ± SEM. ∗P < 0.05 vs. baseline, P < 0.01 vs. iron.
Resting FBF 25 50
ACh
100 mmoI/min
450
400
350
%
 R
es
tin
g 
FB
F
300
250
200
150
100
Fig. 4. Forearm blood flow (FBF) response (% of resting FBF) to in-
cremental doses of intra-arterial acetylcholine (ACh) before infusion of
iron sucrose (300 mg, filled circles) or placebo (open circles), and after
infusion of iron sucrose (filled triangle) and placebo (open triangle).
Mean ± SEM.
The endothelium-independent vasodilator GTN in-
creased resting FBF to 232 ± 22% and 234 ± 18% in the
iron or placebo groups, respectively (P = NS between
groups). Iron or placebo had no effect on GTN-induced
vasodilation, FBF increased to 258±21% and 270±30%,
respectively (P = NS vs. baseline and between groups)
(Fig. 5).
The NO-synthase inhibitor L-NMMA decreased rest-
ing FBF to 70 ± 4% and 74 ± 4% before iron or placebo
infusions, respectively (P = NS between groups). Again,
iron or placebo infusion did not influence vasoconstric-
tion to L-NMMA, which decreased FBF to 72 ± 3% and
73 ± 4%, respectively (P = NS vs. baseline and between
groups) (Fig. 6). Absolute changes in FBF in response to
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Fig. 5. Forearm blood flow (FBF) response (% of resting FBF) to incre-
mental doses of intra-arterial glycerol-trinitrate (GTN) before infusion
of iron sucrose (300 mg, filled circles) or placebo (open circles), and af-
ter infusion of iron sucrose (filled triangle) and placebo (open triangle).
Mean ± SEM.
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Fig. 6. Forearm blood flow (FBF) response (% of resting FBF) to incre-
mental doses of intra-arterial L-N-mono-methyl-arginine (L-NMMA)
before infusion of iron sucrose (300 mg, filled circles) or placebo (open
circles), and after infusion of iron sucrose (filled triangle) and placebo
(open triangle). Mean ± SEM.
acetylcholine, GTN, and L-NMMA in the intervention
arm were also not different between groups (data not
shown).
Adverse events
Study-related adverse events included paresthesia in
the extremities during FBF measurements (N = 4 in the
iron, N = 3 in the placebo group). Two patients per group
reported pain at the puncture site; one patient in the iron
group developed thrombophlebitis. One patient in each
group reported cephalea. There was no difference in local
or systemic adverse events between the two groups.
DISCUSSION
In this prospective, randomized, placebo-controlled,
double-blind trial we found a significant increase of total
iron, NTBI, and redox-active iron in renal failure patients
after intravenous administration of 300 mg iron sucrose
over two hours. After iron infusions basal FBF was 59%
higher than after placebo administration. In contrast, no
effect of iron sucrose on vascular reactivity, an early in-
dicator of vascular disease, was detectable.
High-dose intravenous iron supplementation is an es-
tablished adjuvant therapy for renal anemia and results
in a decrease of required erythropoietin doses [2, 3, 6,
19]. However, concerns have been raised about a possi-
ble increase in cardiovascular disease risk associated with
intravenous iron therapy. Data from some cohort studies
show a correlation between increased body iron stores
and progression of atherosclerotic lesions, risk of acute
myocardial infarction, and cardiac death [20, 21]. Evi-
dence points to an increased cardiovascular disease risk
in carriers of a hemochromatosis gene mutation (HFE
C282Y) [22], while blood donation has been associated
with reduced risk [23]. Endothelial function as an early in-
dicator of vascular disease is impaired in conditions with
iron overload, such as thalassemia and hemochromatosis
[24, 25]. Conversely, improvement of endothelial function
has been described after application of desferrioxamine
in coronary heart disease [26], as well as after phlebotomy
in hemochromatosis patients [25].
Several mechanisms of the detrimental effect of iron on
the vasculature have been suggested. Labile iron leads
to increased generation of reactive oxygen species and
results in reduced NO availability and endothelial dys-
function. Impaired NO availability might be caused by
accelerated lipid peroxidation [10] or direct inactivation
by NTBI [11, 27]. Furthermore, iron uptake into endothe-
lial cells via transferrin receptors plays an important role
in hydroperoxide-induced intracellular oxidative stress.
Conversely, intracellular oxidative stress, caused by glu-
tathione depletion, triggers transferrin receptor overex-
pression, increases the intracellular labile iron pool, and
results in endothelial cell apoptosis [28].
However, only few in vivo data have been published
about the relationship between intravenous iron therapy,
oxidative stress, and endothelial function. Rooyakkers
et al [29] reported a significant decrease in forearm re-
active hyperemia in healthy volunteers after infusion of
100 mg of iron sucrose, accompanied by an increased gen-
eration of superoxide.
In renal failure patients the relationship between body
iron status and vascular disease is even less well defined
[30]. In these patients, oxidative stress is increased due
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to both the uremic condition and a lower concentration
of antioxidants [31–33]. After intravenous infusion of
100 mg of iron sucrose, a significant increase of trans-
ferrin saturation, NTBI, and malondialdehyde, as well
as a decrease of plasma superoxide dismutase activity,
has been reported in chronic kidney disease and HD pa-
tients, suggesting exacerbation of oxidative stress by in-
travenous iron [12, 34–37]. The infusion of antioxidants,
such as vitamin E or melatonin, reduces oxidative stress
after intravenous iron therapy in dialysis patients [12, 38].
An observational study in HD patients has shown an as-
sociation of carotid artery intima-media thickness with
cumulative intravenous iron dose, serum ferritin, as well
as concentration of advanced oxidation protein products
[39], indicating a potential role of iron-induced oxidative
stress in early stages of atherosclerosis. However, because
of the cross-sectional design, this study does not prove a
causal relationship between long-term intravenous iron
therapy and vascular disease. The other above-mentioned
studies only examined serum markers of iron-induced ox-
idative stress, and there are no such data available for PD
patients.
In the present study, basal FBF after infusion of iron
sucrose was higher than in the placebo group. Thus, it has
to be considered that iron substitution exerted a vasodila-
tory response in the forearms. In animal studies, release
of free iron from intravenously administered iron prepa-
rations has been found to induce hypotension, which has
been attributed to a temporary suppression of adrenergic
vasomotor tone [40]. However, it is difficult to extrapolate
animal data to humans. No systemic vasodilation was de-
tectable in our cohort, as evidenced by a lack of changes
in systemic blood pressure or pulse rate (data not pre-
sented). Furthermore, the change in basal FBF (FBF)
after iron or placebo infusion did not reach level of sig-
nificance between groups. Nevertheless, a vasodilatory
effect of iron might have been counteracted by systemic
homeostatic mechanisms. This is also in agreement with a
previous study, where systemic hypotensive reactions to
intravenous iron sucrose infusion were dose-dependent
and mainly observed after doses higher than 300 mg [6].
In contrast to basal FBF, vascular reactivity is con-
sidered an indicator of early vascular disease. The lack
of association between iron infusion and blood flow re-
activity in our trial compared to previous studies is an
interesting finding. We used a prospective, randomized,
placebo-controlled, double-blind study design to exam-
ine the association between iron therapy and resistance
artery vascular function in dialysis patients, whereas in
the previously mentioned study by Rooyakkers et al [29],
conduit vessels in healthy subjects were assessed under
unmasked time-control conditions. In dialysis patients,
endothelial dysfunction has been described [41, 42]. How-
ever, in our cohort of unselected PD patients FBF was
similar to that seen in healthy subjects [43]. This is in line
with other findings, where arterial wall distensibility was
impaired in HD, but not in PD patients [44]. These dif-
ferences might be attributed to lower comorbidity in PD
patients [45], different medication, or iron status between
dialysis patient populations. In contrast to the study by
Rooyakkers et al [29], we have used a higher dose of
iron sucrose (300 vs. 100 mg), but it was administered
with a slower infusion rate (2.5 mg/min vs. 5 mg/min).
Despite the lack of a detrimental influence of 300 mg of
iron sucrose on vascular reactivity in our study, we found
a marked increase of total iron and NTBI compared to
the placebo group. NTBI is a heterogenous mixture of
complexes, and it is likely that its composition varies with
both extent and type of iron overload [46]. For deleteri-
ous effects on endothelial cells, the availability of redox-
active iron, which is only a part of NTBI, probably is
more important than total body-iron stores or dose of
iron. In the present study, we also found a significant in-
crease of redox-active iron after administration of iron su-
crose. However, concentrations were smaller than those
reported in thalassemia patients [18]. Therefore, our data
strongly suggest that after infusion most iron which can
be detected by the mobilizer-dependent NTBI-assay is
bound to serum components and is redox-inactive, thus
not affecting vascular reactivity. In this context, citrate
and albumin are discussed as possible ligands of NTBI
[46].
There are some limitations to this study. We did not
find an acute effect of iron sucrose on forearm blood
flow reactivity. However, a possible long-term effect of
larger intravenous iron doses on vascular function and
cardiovascular morbidity of dialysis patients cannot be
excluded. Furthermore, since measurements of FBF re-
activity were conducted immediately after infusions, de-
layed effects of intravenous iron cannot be ruled out. The
power of this study was calculated based on an expected
difference in vascular function between iron and placebo
infusion of at least 75%. The patient number may have
been too low to detect smaller differences between the
two groups. However, the almost identical forearm blood
flow dose-response curves (see Figs. 4–6) make even such
smaller differences between iron and control group pa-
tients unlikely. The gold standard strain-gauge plethys-
mography was used to measure vascular function in this
study. We have previously demonstrated that drug reac-
tivity to ACh and GTN does not depend on basal FBF
in this model [15]. Therefore, a minor change in forearm
basal vascular tone does not influence our finding on un-
altered vascular reactivity in subjects with PD. Of note,
absolute changes in FBF in response to the vasoactive
substances were also not different between groups.
Despite careful randomization, serum-iron and trans-
ferrin saturation at baseline were slightly lower in the
iron group compared to the control group. However, the
marked increase of iron after infusion of 300 mg of iron
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sucrose should have been appropriate to show effects
on vascular function if present, even when supposing a
higher buffering capacity for iron by transferrin in this
group. Finally, vascular reactivity was subject to diurnal
variability, with higher vasodilatory responses to Ach and
GTN after infusion of iron or placebo, respectively. How-
ever, there was no difference detectable between ran-
domly allocated patient groups.
CONCLUSION
A single intravenous infusion of 300 mg of iron sucrose
did not impair FBF reactivity as measured by plethysmog-
raphy in dialysis patients, despite a marked elevation of
total iron and NTBI, as well as a significant increase of
redox-active iron. However, basal FBF was increased by
iron sucrose and the possible impact of iron-induced va-
sodilation has to be considered, especially when higher
doses of iron sucrose are infused. Prospective trials are
needed to study long-term influences on cardiovascular
mortality in patients requiring high-dose intravenous iron
therapy.
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